Wada Hiroshi, Nagano Hiroaki, Dono Keizo, Kondo Motoi, Yamamoto Tameyoshi, Ota Hideo, Nakamura Masato, Yoshioka Shinichi, Damdinsuren Bazarragchaa, Yubo Yang, Marubashi Shigeru, Miyamoto Atsushi, Umeshita Koji, Nakamori Shoji, Sakon Masato, Monden Morito
Dept of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University.
Gan To Kagaku Ryoho. 2004 Oct;31(11):1711-3.
The patients of unresectable cholangiocellular carcinoma (CCC) have extremely poor prognosis. Case 1 was a 72-year-old male who had CCC in the left lobe of liver with intrahepatic metastasis. From June 2003, he received hepatic arterial infusion chemotherapy (FAP: 5-fluorouracil 250 mg/day continuous infusion, day 1-5, adriamycin 10 mg/day, day 1, and CDDP 10 mg/day, day 1). After 5 courses, abdominal CT revealed that the main tumor had regressed. Case 2 was a 66-year-old male who had CCC with portal vein tumor thrombus of anterior branch (Vp2). He received FAP arterial infusion chemotherapy that was a same regimen as with the case 1 patient. After 5 courses were administered, Abdominal CT revealed that the size of the main tumor at S8 had not changed, and that portal vein tumor thrombus had disappeared. In both cases, there was no complication related to the chemotherapy. They are alive for more than 1 year after chemotherapy had started. FAP hepatic arterial infusion chemotherapy might be promising as an effective therapy for non-resectable CCC without extra hepatic metastasis.
不可切除的胆管细胞癌(CCC)患者预后极差。病例1是一名72岁男性,患有左肝叶CCC伴肝内转移。从2003年6月起,他接受肝动脉灌注化疗(FAP:5-氟尿嘧啶250毫克/天持续输注,第1 - 5天,阿霉素10毫克/天,第1天,顺铂10毫克/天,第1天)。5个疗程后,腹部CT显示主要肿瘤缩小。病例2是一名66岁男性,患有CCC伴门静脉前支肿瘤血栓形成(Vp2)。他接受了与病例1相同方案的FAP动脉灌注化疗。5个疗程后,腹部CT显示S8主要肿瘤大小未变,但门静脉肿瘤血栓消失。在这两个病例中,均无与化疗相关的并发症。化疗开始后他们存活超过1年。FAP肝动脉灌注化疗作为无肝外转移的不可切除CCC的有效治疗方法可能很有前景。